Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03625934 |
Recruitment Status : Unknown
Verified August 2018 by Viravaxx AG.
Recruitment status was: Recruiting
First Posted : August 10, 2018
Last Update Posted : August 10, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to
- elicit a robust protective IgG immune response in vaccine naive subjects
- in subjects who failed to demonstrate seroconversion after treatment with a licensed hepatitis B vaccine and
- in patients chronically infected with HBV.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis B | Biological: VVX001 Biological: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 84 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Study to Evaluate the Induction of HBV Virus Neutralizing Antibodies in Healthy Vaccine Naive Adults and Non-responders and in Patients Chronically Infected With HBV Using VVX001 |
Actual Study Start Date : | August 6, 2018 |
Estimated Primary Completion Date : | August 31, 2020 |
Estimated Study Completion Date : | December 20, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: VVX001 (20 micrograms)
Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
|
Biological: VVX001
5 s.c. injections of 20 micrograms of VVX001 four weeks apart |
Placebo Comparator: Placebo
Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
|
Biological: Placebo
5 s.c. injections of matching Placebo four weeks apart |
- PreS specific IgG antibodies [ Time Frame: 4 weeks after the last injection of study drug ]Titer of PreS specific IgG antibodies
- PreS specific IgG, IgG1 and IgG4 antibodies [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]Titers of PreS specific IgG, IgG1 and IgG4 antibodies
- HbSAg specific antibodies [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]Titers of HbSAg specific antibodies
- Suppression of HBV infection [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]Suppression of HBV infection in HepG2-NTCP cells using HBV strain D3 in cell culture with patient sera
- T cell proliferation [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]Proliferation of PreS specific CD4 and CD8 T cells
- HbSAg titers [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]HbS Antigen titers will be measured in chronically infected patients
- HBV DNA load [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]HBV DNA load will be measured by PCR in chronically infected patients
- HBVcrAg titers [ Time Frame: 4 weeks and 6 months after the last injection of study drug ]HBVcrAG titers will be measured in chronically infected patients
- Adverse events [ Time Frame: up to 52 weeks ]Frequency, intensity and relatedness of adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Cohort 1: hepatits B vaccine naive subjects Seronegative for anti-HBs and anti-HBc antibodies and for HBs Antigen
- Cohort 2: Subjects who failed to develop a protective immune response upon standard vaccination with a licensed hepatitis B vaccine (<10 IU/L anti HbS antibodies) Seronegative for anti-HbS (<10 IU/L) and anti-HBc antibodies and for HbSAg
-
Cohort 3: Parameters confirmed at screening during the past 12 months
- HBeAg negative;
- HbSAg positive at screening <3000 IU/ml;
- HBV viral load <2000 IU/ml
- ALT Levels ≤ULN at screening
-
Cohort 4a: Parameters confirmed at screening during the last 12 months
- HBeAg negative;
- HbSAg positive <1000 IU/ml
- HBV DNA not detectable for at least 2 years
- History of nucleos(t)die Treatment for at least 3 years
- Willingness to discontinue NUC treatment during study
- ALT levels ≤ULN at screening
-
Cohort 4b: in addition to cohort 4a:
- willingness to discontinue NUC treatment 6 weeks before entering the Study
-
ALT Levels ≤ULN 6 weeks before entering the study and
- 5x ULN at screening
Exclusion Criteria:
- Pregnant or breast-feeding females, adequate contraception required during the treatment phase
- History of grass pollen allergy
- Co-infection with HCV, HDV, HIV
- History of auto-immune hepatitis
- Elevated Levels of Alpha-Fetoprotein (AFP) >100 ng/ml
- Documented history of decompensated liver disease (albumin <3.5 g/dl and bilirubin >1.3 mg/dl)
- Autoimmune disorders, transplant recipients, use of immunosuppressive or immune modulating agents
- Oral corticosteroids of 20 mg/week within the past 4 weeks prior to screening
- History of treatment with PEG-IFN of IFN for at least 1 year prior to screening
- History of evidence or conditions associated with chronic liver disease
- Acute fever at time of enrolment
- History of alcohol abuse
- Planned administration of a vaccine not foreseen by study protocol in the period starting 30 days before first product administration and during the entire study period with exception of influenza vaccine
- History of Cancer
- Other severe co-morbid conditions and concurrent medication making the subject unsuitable for participation
- blood or plasma donation within 1 month of study enrolement and during the course of the study
-
For all patients with chronic HBV infection:
- Total bilirubin >2x ULN confirmed by repeat testing within 2 weeks, unless historical documentation of Gilbert's syndrome
- Documented or suspected hepatocelluar carcinoma
- Presence of cholangitis, cholecystitis or bile duct obstruction
- Liver cirrhosis assessed by fibroscan with elastography <9kPa within the previous 12 months and FIB-score <3.2 at study entry

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03625934
Contact: Rainer Henning, PhD | +4317966296 ext 114 | r.henning@viravaxx.com | |
Contact: Ghazaleh Gouya, MD | +436504704206 | gouya@gouya-insights.com |
Austria | |
Medical University of Vienna | Recruiting |
Vienna, Austria, 1090 | |
Contact: Ursula Wiedermann, MD +431 40160 38290 ursula.wiedermann@meduniwien.ac.at | |
Contact: Petra Munda, MD +43 1 40400 4741 petra.munda@meduniwien.ac.at |
Principal Investigator: | Petra Munda, MD | Medical University Vienna |
Publications of Results:
Responsible Party: | Viravaxx AG |
ClinicalTrials.gov Identifier: | NCT03625934 |
Other Study ID Numbers: |
VVX001-CS001 |
First Posted: | August 10, 2018 Key Record Dates |
Last Update Posted: | August 10, 2018 |
Last Verified: | August 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Hepatitis B Hepatitis Liver Diseases Digestive System Diseases |
Hepadnaviridae Infections DNA Virus Infections Virus Diseases Hepatitis, Viral, Human |